Background: Salvage high-intensity focused ultrasound (HIFU) and cryotherapy (CRYO) have emerged as interesting alternatives in the treatment of local radio-recurrent prostate cancer. Currently, recommendations concerning the use of CRYO and HIFU in the salvage setting are still evolving. Aim: The objective of this review was to analyze the results from studies on CRYO and HIFU as salvage treatment in local radio-recurrent prostate cancer. Materials and Methods: A National Center for Biotechnology Information PubMed search (www.pubmed.gov) was conducted from 1993 to 2011 using medical subject headings ‘High-Intensity Focused Ultrasound’, ‘Cryotherapy’, ‘Local Radio-Recurrent’ and ‘Prostate Cancer’. Results: In the past years, there have been several published series demonstrating promising acceptable morbidity and oncological outcomes in the short term for HIFU and in the intermediate term for CRYO. The introduction of newer-generation devices and technical modifications has facilitated reduction of complications associated with the procedures. As with any salvage treatment, careful patient selection and subsequent follow-up are principal points. Conclusions: HIFU and CRYO are promising salvage treatments in patients with local radio-recurrent prostate cancer. The risk of significant complications in the salvage setting is higher compared with primary therapy; therefore, the patients must be informed about the risk of complications and the modality of treatment. However, only further evaluation in formal prospective clinical trials will hopefully confirm their role in clinical practice.

Keywords:
High-intensity focused ultrasound, Cryotherapy, Local radio-recurrent prostate cancer
1.
Zietman AL, Bae K, Slater JD: Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology. J Clin Oncol 2010;28:1106–1111.
2.
Agarwal PK, Sadetsky N, Konety BR, Resenick MI, Carroll PR: Cancer of the prostate Strategic Urological Research Endeavor (CAPSURE). Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care and outcomes. Cancer 2008;112:307–314.
3.
D’Amico A, Altschuler M, Whittington R, Kao G, Malkowicz SB, Wein A: The use of clinical parameters in an interactive statistical package to predict pathological features associated with local failure after radical prostatectomy for prostate cancer. Clin Perform Qual Health Care 1993;1:219–222.
4.
Prepelica KL, Okeke Z, Murphy A, Katz AE: Cryosurgical ablation of the prostate: high-risk patient outcomes. Cancer 2005;103:1625–1630.
5.
Chin JL, Touma N, Pautler SE, Guram KS, Bella AJ, Downey DB, et al: Serial histopathology results of salvage cryoablation for prostate cancer after radiation failure. J Urol 2003;170:1199–1202.
6.
American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035–1041.
7.
Pickles T, Kim-Sing C, Morris WJ, Tyldesley S, Paltiel C: Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys 2003;57:11–18.
8.
Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965–974.
9.
Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, et al: First analysis of the long-term results with transrectal HIFU in patients with localized prostate cancer. Eur Urol 2008;53:1194–1201.
10.
Shinohara K, Rhee B, Presti JC Jr, Carroll PR: Cryosurgical ablation of prostate cancer: patterns of cancer recurrence. J Urol 1997;158:2206–2210.
11.
Ng CK, Moussa M, Downey DB, Chin JL: Salvage cryoablation of the prostate: follow-up and analysis of predictive factors for outcome. J Urol 2007;178:1253–1257.
12.
Bostwick DG, Egbert BM, Fajardo LF: Radiation injury of the normal and neoplastic prostate. Am J Surg Pathol 1982;6:541–551.
13.
Molinié V, Mahjoub WK, Balaton A: Histological modifications observed in prostate after preserving treatments for prostate cancer and their impact on Gleason score interpretation. Ann Pathol 2008;28:363–373.
14.
Crook J, Malone S, Perry G, et al: Post-radiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000;48:355–367.
15.
Pucar D, Sella T, Schoder H: The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr Opin Urol 2008;18:87–97.
16.
Rinnab L, Simon J, Hautmann RE, et al: Choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol 2009;27:619–625.
17.
Mallick S, Dufour A, Fouques Y, Bensadoun H: Salvage therapy using high-intensity focused ultrasound for local recurrence of prostate cancer after radiation therapy (abstract). Eur Urol Suppl 2006;5:132.
18.
Gelet A, Chapelon J, Poissonnier L, Bouvier R, Colombel M, Curiel L, et al: Local recurrence of prostate cancer after external beam radiation: early experience of salvage therapy using high-intensity focused ultrasound (abstract. Eur Urol Suppl 2006;5:133.
19.
Murat FJ, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O, et al: Mid-term results demonstrate salvage high-intensity focused ultrasound as an effective and acceptably morbid salvage treatment option for locally radio-recurrent prostate cancer. Eur Urol 2009;55:640–647.
20.
Colombel M, Poissonier L, Martin X, Gelet A: Clinical results of the prostate HIFU project. Eur Urol Suppl 2006;5:491–494.
21.
Nguyen P, D’Amico AV, Lee AK, Su WW: Patient selection, cancer control and complications after salvage local therapy for post- radiation prostate-specific antigen failure. Cancer 2007;110:1417–1428.
22.
Poissonnier L, Chapelon JY, Rouviere O, Curiel L, Bouvier R, Martin X, et al: Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007;51:381–387.
23.
Uchida T, Illing RO, Cathcart PJ, Emberton M: To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 2006;98:537–539.
24.
Ben Cheikh A, Girouin N, Ryon-Tapponier P, et al: MR detection of local prostate cancer recurrence after transrectal high-intensity focused ultrasound treatment: preliminary results. J Radiol 2008;89:571–577.
25.
Blana A, Rogenhofer S, Ganzer R, Wild PJ, Wieland WF, Walter B: Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 2006;24:585–590.
26.
Cooper IS, Hirose T: Application of cryogenic surgery to resection of parenchymal organs. N Engl J Med 1966;274:15–18.
27.
Chalasani V, Gardi L, Martinez CH, Downey DB, Fenster A, Chin JL: Contemporary technique of intraoperative three-dimensional ultrasonography-guided transperineal prostate cryotherapy. Can Urol Assoc J 2009;3:136–141.
28.
Chin JL, McLoughlin RF, Downey DB: Three-dimensional ultrasound and magnetic resonance imaging of pelvic anatomy: potential for complications from minimally invasive procedures. J Endourol 1999;13:451–459.
29.
Chin JL, Downey DB, Onik G, Fenster A: Three-dimensional prostate ultrasound and its application to cryosurgery. Tech Urol 1996;2:187–193.
30.
Ghafar MA, Johnson CW, De La Taille A, et al: Salvage cryotherapy using argon-based system for locally recurrent prostate cancer after radiation therapy: the Columbian Experience. J Urol 2001;166:1333–1337.
31.
Ismail M, Ahmed S, Kastner C, Davies J: Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int 2007;100:760–764.
32.
Williams AK, Martinez CH, Lu C, Ng CK, Pautler SE, Chin JL: Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer. Eur Urol 2011;60:405–410.
33.
Philippou P, Yap T, Chinegwundoh F: Third-generation salvage cryotherapy for radio-recurrent prostate cancer: a centre’s experience. Urol Int 2012;88:137–144.
34.
Izawa JI, Madsen LT, Scott SM, et al: Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol 2002;20:2664–2671.
35.
Pisters LL, Leibovici D, Blute M, Zincke H, Sebo TJ, Slezak JM, et al: Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol 2009;182:517–527.
36.
Chin JL, Pautler SE, Mouraviev V, et al: Results of salvage cryoablation for prostate cancer after radiation: identifying predictors of treatment failure and complications. J Urol 2001;165:1937–1941.
37.
Langenhuijsen JF, Broers ESP, Vergunst H: Cryosurgery for prostate cancer: an update on clinical results of modern cryotechnology. Eur Urol 2009;55:76–86.
38.
Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J: Male lumpectomy focal therapy for prostate cancer using cryoablation. Urology 2007;70:16–21.
39.
Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU: Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis 2011;14:46–52.
40.
Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M: The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int 2010;106:1607–1611.
41.
Benoit RM, Cohen JK, Miller RJ: Cryosurgery for prostate cancer: new technology and indications. Curr Urol Rep 2000;1:41–47.
42.
Bahn DK, Lee F, Silverman P, et al: Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. Clin Prostate Cancer 2003;2:111–114.
43.
Donnelly BJ, Saliken JC, Ernst DS, et al: Role of transrectal ultrasound-guided salvage cryosurgery for recurrent prostate carcinoma after radiation therapy. Prostate Cancer Prostatic Dis 2005;8:235–242.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.